Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia

Maury, Sébastien; Chevret, Sylvie; Thomas, Xavier; Heim, Dominik; Leguay, Thibaut; Huguet, Françoise; Chevallier, Patrice; Hunault, Mathilde; Boissel, Nicolas; Escoffre‐Barbe, Martine; Hess, U.; Vey, Norbert; Pignon, Jean‐Michel; Braun, Thorsten; Marolleau, Jean‐Pierre; Cahn, Jean‐Yves; Chalandon, Yves; Lhéritier, Véronique; Beldjord, Kheïra; Béné, Marie C.; Ifrah, Norbert; Dombret, Hervé

doi:10.1056/nejmoa1605085

Cited by 299 publications

(209 citation statements)

References 29 publications

Supporting

Mentioning

198

Contrasting

Unclassified

Order By: Relevance

“…Patients with AML or RAEB-2 received a first cycle of cytarabine (200mg/m 2 over 7 days) with idarubicine (12mg/m 2 ) or daunorubicine (60mg/m 2 ) over 3 days (13) and a second cycle with high dose cytarabine, according to ongoing HOVON/SAKK protocols. Patients with ALL were treated according to the GRAALL 2005 protocol (14). Neutropenia was defined by an absolute neutrophils count (ANC) <500 cells/mm3.…”

mentioning

confidence: 99%

Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy

Brunel¹,

Wójtowicz²,

Lamoth³

et al. 2018

Haematologica

View full text Add to dashboard Cite

mentioning

confidence: 99%

Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy

Brunel¹,

Wójtowicz²,

Lamoth³

et al. 2018

Haematologica

View full text Add to dashboard Cite

“…This agent is used in patients with HER-2/neu-positive breast cancer and metastatic gastrointestinal (GI) cancers and in patients with other forms of cancer that express HER-2/neu (31-34); (vii) Rituximab is a human/murine MAB that has been approved for the treatment of non-Hodgkin's lymphoma and also lymphocytic leukemia. It may also be effective for the treatment of other tumours and autoimmune diseases such as lupus erythematosus (27,(35)(36)(37)(38) .…”

Section: Antitumor Monoclonal Antibodies (Mabs)mentioning

confidence: 99%

Monoclonal Antibodies for the Treatment of Cancer

Pento

2017

View full text Add to dashboard Cite

Abstract.Cancer metastasis is responsible for most of the morbidity and mortality associated with cancer. Cancer metastatic progression is a multiple step process which includes enhanced cell proliferation, release of proteolytic enzymes, cell motility and invasion, angiogenesis and establishment of a supportive microenvironment at the sites of metastatic growth (1, 2).Traditional cancer therapy has focused on removal or destruction of tumour cells by surgery, radiation and rather nonselective types of chemotherapy. Surgery and radiation are often effective with tumours which are localized and have not metastasized to multiple sites throughout the body. Chemotherapy appears to be most effective in the treatment of metastatic cancer; however, typical chemotherapeutic agents such as cisplatin, methotrexate, vincristine, 5-fluorouracil among many others, focus on rapidly growing tissues since cancer cells are relatively rapidly growing. Thus, cancer chemotherapy often results in a high incidence of unwanted and damaging side-effects in rapidly-dividing normal tissues, such as blood cells and cells lining gastrointestinal tract.With a greater understanding of cellular chemistry and genomics during the past twenty years, cellular targets that are unique to cancer cells have been identified and chemotherapeutic agents which specifically bind to, destroy or otherwise inactivate these unique cellular targets have been developed. These agents which impede these unique or overexpressed cancer targets tend to be more selective, -thus more effective with fewer side-effects than traditional, nonselective chemotherapy. They target critical checkpoints which are often overexpressed on rapidly growing and malignant cancer cells, such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) and tyrosine kinase. Therefore, cancer Immunotherapy is an exciting and relatively new method to selectively block critical checkpoints in the process of cancer development (3, 4).

show abstract

“…Rituximab is a chimeric monoclonal antibody, approved in 1997 by the Food and Drug Administration (FDA) in the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, but its efficacy is also being assessed in combination with chemotherapy in adults with B-cell acute lymphoblastic leukemia. In several studies, targeting CD20 was related to obtaining a prominent improvement of chemotherapy results in the Philadelphia chromosome-negative BCP-ALL [55][56][57]. Ofatumumab is also developed to target CD20; however, its binding site is closer to the cell membrane and with greater avidity than rituximab.…”

Section: To Bridge the Tumor Cell To The Killermentioning

confidence: 99%

Immunotherapy in Pediatric Acute Leukemia: A Novel Magic Bullet or an Illusory Hope?

Barełkowska¹,

Derwich²

2017

Unique Aspects of Anti-Cancer Drug Development

View full text Add to dashboard Cite

The last decade became the renaissance for investigating and exploring the potential role of immunotherapy in pediatric acute leukemia (AL). It is beyond question that there is an interaction between innate immune system and hematological malignancy. Leukemia cells inhibit the host immune response according to multiple mechanisms, but exploiting the innate immune system mechanisms can overcome the resistance to the conventional treatment. What is the role of immunotherapy in pediatric AL treatment? Does it have the potential to substitute or combine the standard chemotherapy? What is the best possible timing to take advantage of immune interventions? This review is considered to follow through the possible treatment options including their foundation, strong and weak points, but also information about possible implementation into the clinical practice.

show abstract

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia

Abstract: Adding rituximab to the ALL chemotherapy protocol improved the outcome for younger adults with CD20-positive, Ph-negative ALL. (Funded by the Regional Clinical Research Office, Paris, and others; ClinicalTrials.gov number, NCT00327678 .).

Cited by 299 publications

References 29 publications

Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy

Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy

Monoclonal Antibodies for the Treatment of Cancer

Immunotherapy in Pediatric Acute Leukemia: A Novel Magic Bullet or an Illusory Hope?

Contact Info

Product

Resources

About